Program Information


Personalized Therapy for Patients with Antibody-Mediated Rejection: A Care Team ForumSM

Tuesday, 17 September 2019
Registration & Welcome Refreshments

16:35 – 17:05
Symposium and Panel Discussion
17:05 – 18:35



Bella Center Copenhagen
Room C1M2
Center Boulevard 5
2300 Copenhagen, Denmark


PATIENT-CENTRIC SYMPOSIUM
Don’t miss this engaging panel discussion, enhanced with evidence-based cases on antibody-mediated rejection (AMR) in solid organ transplant (SOT) patients. Faculty will be joined by a renal transplant patient with experience in AMR, to add their perspective on the care delivery experience.


PROGRAM AGENDA

16:35 – 17:05
 
Registration & Welcome Refreshments
17:05 – 17:10
 
Welcome and Introductions
Klemens Budde, MD
17:10 – 17:35
 
Clinical Case 1 – Patient with Active Acute AMR
Klemens Budde, MD; Michael Mengel, MD; and Panel (including AMR Patient)
Audience Q&A
17:35 – 18:00
 
Clinical Case 2 – Patient with Chronic Active AMR
Georg Böhmig, MD; Michael Mengel, MD; and Panel (including AMR Patient)
Audience Q&A
18:00 – 18:25
 
Clinical Case 3 – Patient with Refractory AMR
Fritz Diekmann, MD; Michael Mengel, MD; and Panel (including AMR Patient)
Audience Q&A
18:25 – 18:35
 
Audience Q&A, Closing Remarks
Panel

Klemens Budde, MD (Chair)
Senior Consultant
Department of Nephrology and Intensive Care
Charité Universitätsmedizin
Berlin, Germany

Georg Böhmig, MD
Associate Professor
Division of Nephrology and Dialysis
Department of Medicine III
Medical University of Vienna
Vienna, Austria
Fritz Diekmann, MD
Associate Professor
Chief, Kidney Transplant Unit
Hospital Clinic de Barcelona
Barcelona, Spain
Michael Mengel, MD
Professor and Chair
Department of Laboratory Medicine and Pathology
University of Alberta
Edmonton, Canada


EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

  • Describe the pathophysiology of antibody-mediated rejection (AMR), including the significance of the activation of the complement system and cytokine pathways in order to effectively and aggressively institute treatment
  • Discuss existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
  • Select appropriate therapeutic agents and protocols to treat AMR and prolong allograft survival

TARGET AUDIENCE
This activity has been designed to meet the educational needs of clinicians who manage antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).


PROVIDER STATEMENT
This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with Advancing Knowledge in Healthcare (AKH) Inc. All faculty and planner conflicts of interest were identified and resolved and AKH has reviewed the content and determined it to be fair, balanced, and without commercial bias.


STATEMENT OF SUPPORT
This activity is supported by an independent educational grant from CSL Behring.


FEE STATEMENT
There is no fee for this educational activity.


QUESTIONS?
Please contact Stephanie Kielt at skielt@rmei.com if you have any questions.




FOLLOW RMEI
Facebook  Twitter  RMEI Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.